RELATIONSHIPS OF CLINICAL RESPONSE TO RELEVANT MOLECULAR SIGNAL DURING PHASE I TESTING OF AURORA KINASE A INHIBITOR: RETROSPECTIVE ASSESSMENT

Relationships of Clinical Response to Relevant Molecular Signal During Phase I Testing of Aurora Kinase A Inhibitor: Retrospective Assessment.

SURVIVIN-TARGETED IMMUNOTHERAPY DRIVES ROBUST POLYFUNCTIONAL T CELL GENERATION AND DIFFERENTIATION IN ADVANCED OVARIAN CANCER PATIENTS

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

PHASE I TRIAL OF BI-SHRNA STMN1 BIV IN REFACTORY CANCER

Phase I Trial of bi-shRNA STMN1 BIV in Refactory Cancer. Molecular Therapy 2015 Jun;23(6):1123-30.

LIPOSOMAL INSULIN PROMOTERTHYMIDINE KINASE GENE THERAPY FOLLOWED BY GANCICLOVIR EFFECTIVELY ABLATES HUMAN PANCREATIC CANCER IN MICE

Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. Cancer Lett. 2015 Apr 10;359(2):206-10.

Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma.

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

PILOT TRIAL OF (FANG™) IMMUNOTHERAPY IN EWING’S SARCOMA

Pilot Trial of FANG™ Immunotherapy in Ewing’s Sarcoma. Molecular Therapy 2015 Jun;23(6):1103-9.

AZD9150, A NEXT-GENERATION ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF STAT3, WITH EARLY EVIDENCE OF CLINICAL ACTIVITY IN LYMPHOMA AND LUNG CANCER

Next-Generation Antisense Oligonucleotide Inhibitor of STAT3, with Early Evidence of Clinical Activity in Lymphoma and Lung Cancer. Science Translational Medicine 2015 Nov 18;7(314):314ra185.

PHASE I DOSE-ESCALATION STUDY OF THE MULTIKINASE INHIBITOR LENVATINIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND IN AN EXPANDED COHORT OF PATIENTS WITH MELANOMA

Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma.

MELANOMA PATIENT GIVEN MONTHS TO LIVE SHARES SURVIVAL STORY

In April of last year, Kimberly Hinshaw felt a small, pea-sized bump on her thigh. It didn’t hurt and she says if she hadn’t been applying lotion she probably never would have noticed it.

EWING’S SARCOMA SCIENTIFIC POSTER PRESENTATION

Ewing’s Sarcoma Scientific Abstract Presentation Slated For American Society of Clinical Oncology Annual Meeting